TNKase® (Tenecteplase)
TNKase® (Tenecteplase) is a single-bolus thrombolytic, or clot-busting agent, approved by the U.S. Food and Drug Administration for use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms.
First Five-Second, Single-Bolus Thrombolytic TNKase in the Treatment of Heart Attack
Important Safety Information TNKase therapy should not be used in the following conditions due to an increased risk of bleeding: active internal bleeding, history of stroke, brain or spinal surgery or a serious head injury within 2 months, brain tumor, an abnormal connection between veins and arteries, or abnormal bulge in the wall of an artery, problems with blood clotting, and severe uncontrolled high blood pressure.
All thrombolytic agents increase the risk of bleeding, including bleeding in the brain, and should be used only in eligible patients. In addition, drug therapy that dissolves blood clots increases the risk of stroke, including stroke caused by bleeding into the brain, particularly in elderly patients. In serious heart attack patients, physicians should choose either drug therapy that dissolves blood clots or a mechanical means to remove the clot as the main treatment strategy.
Please visit http://www.tnkase.com for the TNKase full prescribing information for additional important safety information.